Tilray | TRLY - Selling And Administration Expenses

Stock Price
10.64
Daily Change
-0.16 -1.48%
Monthly
-10.89%
Yearly
688.15%
Q1 Forecast
10.37

Tilray reported $24.85M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acasti Pharma USD 1.96M 180K Sep/2025
Akebia Therapeutics USD 25.74M 1.93M Mar/2025
Alaunos Therapeutics USD 585K 260K Sep/2025
Aurora Cannabis CAD 41.79M 3.84M Sep/2025
Avita Medical AUD 20.98M 253K Jun/2025
Canopy Growth CAD 29.53M 999K Sep/2025
Cronos Group USD 14.56M 1.33M Sep/2025
Dianthus Therapeutics USD 8.2M 669K Sep/2025
Divis Laboratories Ltd INR 3.4B 10M Jun/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
IQVIA Holdings USD 468M 46M Dec/2025
Knight Therapeutics CAD 25.48M 119K Sep/2024
Moderna USD 308M 40M Dec/2025
Organigram Holdings CAD 8.86M 499K Sep/2025
Organon & Co USD 399M 54M Sep/2025
Revvity USD 251.73M 9.82M Dec/2025
Tectonic Therapeutic USD 4.96M 190K Sep/2025
Tilray USD 24.85M 1.7M Sep/2025
Viatris USD 886.6M 42.1M Sep/2025
Xeris Pharmaceuticals USD 46.46M 2.07M Sep/2025